by Madaline Spencer | Jul 27, 2026
The US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received a prior ROS1 kinase inhibitor. ROS1-positive NSCLC...
by Madaline Spencer | Jul 27, 2026
Joanne Quan, MD, Chief Medical Officer of Mirum Pharmaceuticals, discusses results from the PROGRESS study of zilurgisertib in patients with fibrodysplasia ossificans progressiva (FOP). FOP is a disorder in which skeletal muscle and connective tissue are...
by Madaline Spencer | Jul 23, 2026
Robert Hal Scofield, MD, Professor of Medicine, at the University of Oklahoma and Oklahoma Medical Research Foundation, discusses the DAHLIAS clinical trial evaluating nipocalimab in Sjögren’s disease (SjD). SjD is an autoimmune disorder that largely...
by Madaline Spencer | Jul 21, 2026
Oksana Hamidi, DO, Associate Professor at the University of Texas Southwestern Medical Center, discusses 2-year data on crinecerfont for the treatment of patients with congenital adrenal hyperplasia (CAH). CAH refers to a group of genetic conditions that...
by Madaline Spencer | Jul 17, 2026
Elif Oral, MD, Professor at the University of Michigan, discusses advances in lipodystrophy research presented at ENDO 2026. Lipodystrophies are rare metabolic disorders characterized by the loss of adipose tissue. This leads to complications such as...
